Over the past 10 years, the treatment for lung cancer has drastically changed from chemotherapy - as the unique sole modality - to targeted therapies, immunotherapy and refinement of complex multimodality treatments. The de- velopment of targeted therapies and potent agents such as tyrosine kinase inhibitors shifted the therapeutic approach towards personalised medicine, where patients are treated in the context of their driver mutations